ANIX

ANIXA BIOSCIENCES, INC.

ANIX · CIK 715446 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20172025
Net Income−$11M
20172025
Operating CF−$7M
20172025
Free Cash Flow
20172025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue—$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense—————$0.0B$0.0B$0.0B
Operating Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-0.34$-0.39$0.32$-0.45————
EPS (Diluted)$-0.34$-0.39$0.32—————

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Assets$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B———$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$0.0B$0.0B$-0.0B$-0.0B$-0.0B$-0.0B$0.0B$-0.0B
Capital Expenditures———$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
← Companies